Main > DERMATOLOGY > USA. I. AD>Treat.>JAK1/JAK2 Inh. Cr

---

eam

USA. I. AD>Treat.>JAK1/JAK2 Inh. Cr's subsections
(*) USA Approval Date: 2021. 09.21
Company
Generic Name: Ruxolitinib
JAK: JAnus Kinase
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 11
Patent>UpDate: 2022. 07.19
TM
TM Web-Site

USA. I. AD>Treat.>JAK1/JAK2 Inh. Cr's products
This section has no products